{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:28:02Z","timestamp":1787682482170,"version":"build-2784847793"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.eururo.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T19:18:04Z","timestamp":1537211884000},"page":"767-781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the Literature"],"prefix":"10.1016","volume":"74","author":[{"given":"Giorgio Ivan","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uros","family":"Milenkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Hellstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ralph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.07.005_bib0325","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.sxmr.2015.10.002","article-title":"The genetic basis of Peyronie disease: a review","volume":"4","author":"Herati","year":"2016","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.eururo.2018.07.005_bib0330","series-title":"EAU guidelines on erectile dysfunction, premature ejaculation, penile curvature and priapism","author":"Hatzimouratidis","year":"2017"},{"key":"10.1016\/j.eururo.2018.07.005_bib0335","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/and.12178","article-title":"Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: a prospective, randomised controlled study","volume":"46","author":"Favilla","year":"2014","journal-title":"Andrologia"},{"key":"10.1016\/j.eururo.2018.07.005_bib0340","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1517\/14712598.2010.510509","article-title":"Collagenase Clostridium histolyticum for Dupuytren's contracture","volume":"10","author":"Desai","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.eururo.2018.07.005_bib0345","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bju.13120","article-title":"Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD)","volume":"116","author":"Carson","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.07.005_bib0350","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0355","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1743-6109.2008.01081.x","article-title":"Peyronie's disease intervention trials: methodological challenges and issues","volume":"6","author":"Muller","year":"2009","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0360","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0365","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1743-6109.2011.02519.x","article-title":"Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease","volume":"9","author":"Abern","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0370","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/andr.12368","article-title":"Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study","volume":"5","author":"Favilla","year":"2017","journal-title":"Andrology"},{"key":"10.1016\/j.eururo.2018.07.005_bib0375","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","article-title":"Collagenase versus placebo in the treatment of Peyronie's disease\u2014a double-blind-study","volume":"149","author":"Gelbard","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0380","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s11255-015-1074-1","article-title":"Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease","volume":"47","author":"Gennaro","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0385","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","article-title":"Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial","volume":"177","author":"Greenfield","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0390","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon \u03b1-2b for minimally invasive treatment for Peyronie's disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0395","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1743-6109.2005.00110.x","article-title":"The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease","volume":"2","author":"Kendirci","year":"2005","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0400","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.2047-2927.2012.00018.x","article-title":"Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease","volume":"1","author":"Mehrsai","year":"2013","journal-title":"Andrology"},{"key":"10.1016\/j.eururo.2018.07.005_bib0405","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/j.1939-4640.2000.tb03279.x","article-title":"Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results","volume":"21","author":"Montorsi","year":"2000","journal-title":"J Androl"},{"key":"10.1016\/j.eururo.2018.07.005_bib0410","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jsxm.2017.08.015","article-title":"Treatment of Peyronie's disease with collagenase Clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study","volume":"14","author":"Ralph","year":"2017","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0415","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study","volume":"51","author":"Rehman","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.005_bib0420","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0425","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1111\/j.1743-6109.2010.01924.x","article-title":"Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial","volume":"7","author":"Soh","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0430","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1590\/S1677-5538.IBJU.2015.0598","article-title":"A prospective, randomized, single-blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie's disease: a pilot study","volume":"42","author":"Toscano","year":"2016","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0435","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.juro.2015.03.092","article-title":"The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie's disease","volume":"194","author":"Yafi","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0440","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/j.1939-4640.1999.tb02539.x","article-title":"A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease","volume":"20","author":"Ahuja","year":"1999","journal-title":"J Androl"},{"key":"10.1016\/j.eururo.2018.07.005_bib0445","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","article-title":"Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie's disease","volume":"100","author":"Anaissie","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.005_bib0450","first-page":"665","article-title":"Intralesional recombinant interferon alpha-2b in Peyronie's disease","volume":"53","author":"Astorga","year":"2000","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0455","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.urology.2007.02.042","article-title":"Intralesional verapamil prevents the progression of Peyronie's disease","volume":"69","author":"Bennett","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.005_bib0460","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1464-410x.2001.02139.x","article-title":"Treatment of Peyronie's disease with local interferon-\u03b1 2b","volume":"87","author":"Brake","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.07.005_bib0465","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.urology.2007.01.080","article-title":"Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease","volume":"69","author":"Cavallini","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.005_bib0470","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.SMJ.0000056658.60032.D3","article-title":"Intralesional interferon-\u03b1-2b injections for the treatment of Peyronie's disease","volume":"97","author":"Dang","year":"2004","journal-title":"Southern Med J"},{"key":"10.1016\/j.eururo.2018.07.005_bib0475","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/0974-7796.152048","article-title":"Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie's disease","volume":"7","author":"Dell\u2019Atti","year":"2015","journal-title":"Urol Ann"},{"key":"10.1016\/j.eururo.2018.07.005_bib0480","doi-asserted-by":"crossref","first-page":"E124","DOI":"10.1016\/j.esxm.2017.02.001","article-title":"Changes in the effects of Peyronie's disease after treatment with collagenase Clostridium histolyticum: male patients and their female partners","volume":"5","author":"Goldstein","year":"2017","journal-title":"Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0485","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1743-6109.2008.01108.x","article-title":"Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study","volume":"6","author":"Gontero","year":"2009","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0490","first-page":"291","article-title":"Evaluation of Intralesional injection of Verapamil in treatment of Peyronie's disease","volume":"60","author":"Heidari","year":"2010","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.eururo.2018.07.005_bib0495","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1743-6109.2007.00651.x","article-title":"The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study","volume":"5","author":"Jordan","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0500","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1464-410X.1997.02849.x","article-title":"Intralesional interferon in the treatment of Peyronie's disease: a pilot study","volume":"79","author":"Judge","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0505","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/003655900455422","article-title":"The use of betamethasone and hyaluronidase injections in the treatment of Peyronie's disease","volume":"34","author":"Lamprakopoulos","year":"2000","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0510","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0022-5347(01)64224-1","article-title":"Treatment of Peyronie's disease with intralesional verapamil injection","volume":"158","author":"Levine","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0515","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jsm.12731","article-title":"Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study","volume":"12","author":"Levine","year":"2015","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0520","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","article-title":"Experience with intraplaque injection of verapamil for Peyronie's disease","volume":"168","author":"Levine","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0525","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0022-5347(17)35291-6","article-title":"Intralesional verapamil injection for the treatment of Peyronie's disease","volume":"151","author":"Levine","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0530","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1743-6109.2008.00814.x","article-title":"Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study","volume":"5","author":"Levine","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0535","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/jsm.12400","article-title":"Acute phase Peyronie's disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation","volume":"11","author":"Mart\u00ednez-Salamanca","year":"2014","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0540","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/j.1464-410X.2010.10029.x","article-title":"Defining predictors of response to intralesional verapamil injection therapy for Peyronie's disease","volume":"108","author":"Moskovic","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.07.005_bib0545","first-page":"2105","article-title":"Minimally invasive therapy using intralesional onabotulinumtoxinA in Peyronie's disease","volume":"12","author":"Mu\u00f1oz-Rangel","year":"2015","journal-title":"Urol J"},{"key":"10.1016\/j.eururo.2018.07.005_bib0550","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","article-title":"Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie's disease","volume":"14","author":"Nguyen","year":"2017","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0555","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF02551115","article-title":"Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging","volume":"29","author":"Polat","year":"1997","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0560","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bju.13932","article-title":"Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol","volume":"120","author":"Raheem","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.07.005_bib0565","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1464-410X.2010.09365.x","article-title":"The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease","volume":"106","author":"Raheem","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.07.005_bib0570","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-5347(05)67981-5","article-title":"Iontophoresis for treatment of Peyronie's disease","volume":"163","author":"Riedl","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0575","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.juro.2015.06.096","article-title":"Intralesional injection of interferon-alpha2b improves penile curvature in men with Peyronie's disease independent of plaque location","volume":"194","author":"Stewart","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0580","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11255-008-9408-x","article-title":"The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie's disease","volume":"41","author":"Tuygun","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0585","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000475057","article-title":"Treatment of Peyronie's-disease with local interferon-alpha-2b","volume":"28","author":"Wegner","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0590","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000480857","article-title":"Local interferon-alpha2b is not an effective treatment in early-stage Peyronie's disease","volume":"32","author":"Wegner","year":"1997","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0595","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.urology.2015.03.010","article-title":"Intralesional injections for early Peyronie disease: standardized assessment and analysis of predictive factors for treatment response","volume":"86","author":"Wolff","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.005_bib0600","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","article-title":"Peyronie's disease and injectable collagenase Clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms","volume":"94","author":"Yang","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.005_bib0605","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","article-title":"Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie's disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.07.005_bib0610","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2017.04.045","article-title":"Self-reported clinical meaningfulness early in the treatment course predicts objective outcomes in men undergoing collagenase Clostridium histolyticum injections for Peyronie disease","volume":"106","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.005_bib0615","doi-asserted-by":"crossref","first-page":"E85","DOI":"10.1016\/j.esxm.2016.01.002","article-title":"Intralesional injection of hyaluronic acid in patients affected with Peyronie's disease: preliminary results from a prospective, multicenter, pilot study","volume":"4","author":"Zucchi","year":"2016","journal-title":"Sex Med"},{"key":"10.1016\/j.eururo.2018.07.005_bib0620","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2018.07.005_bib0625","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2018.07.005_bib0630","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.urology.2017.01.054","article-title":"Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease","volume":"104","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.005_bib0635","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","article-title":"Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study","volume":"67","author":"Inal","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.07.005_bib0640","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jsxm.2018.03.084","article-title":"Predictive factors of patients\u2019 and their partners\u2019 sexual function improvement after collagenase Clostridium histolyticum injection for Peyronie's disease: results from a multi-center single-arm study","volume":"15","author":"Cocci","year":"2018","journal-title":"J Sex Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818304834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818304834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:04:40Z","timestamp":1759583080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818304834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0302283818304834"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.07.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734054674.793574536","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}